PolyMVA

Poly-MVA is a uniquely formulated combination of minerals, vitamins and amino acids designed to support cellular energy production and promote overall health. Poly-MVA also replaces specific nutrients that may be depleted during certain therapies. A patented dietary supplement with over 15 years of clinical laboratory research and testing, Poly-MVA is a revolutionary product and the first in a remarkable new category of supplement called lipoic acid palladium complexes (LAPd).

BENEFITS OF POLY-MVA:

• Provides superior antioxidant and free radical protection
• Offers fast acting, immediate absorption for quick results
• Supports energy production at the cellular level
• Enhances quality of life
• Provides nutritional support to those with compromised immune systems
• Promotes health by replenishing nutrients that may be depleted during certain therapies

This article - PolyMVA Information Packet - Garnett McKeen Laboratory Inc. (PDF, 105 kb) presents the scientific basis behind Poly-MVA from studies & investigations conducted by the Garnett McKeen Laboratory Inc.

How can Poly-MVA help your pet?

Animals have very similar cellular functions to humans; in many cases, they are indistinguishable. Just as a human body benefits from the boost in cellular energy, the antioxidant properties and the enhanced nutrition that Poly-MVA provides, your pet can benefit from Poly-MVA for Pets.

Poly-MVA for Pets contains many nutrients crucial to maintaining not only proper nutrition and health, but also to maintaining general quality of life as you pet ages or faces a difficult disease or treatment. Poly-MVA for Pets allows your pet to reach and maintain an optimum level of health and well-being. Through its unique mechanisms of actions, this supplement will help to eliminate the deficiencies and weaknesses that can contribute to the development of serious illness. Read more about Poly-MVA here.

Poly-MVA for Pets provides the powerful antioxidant and cellular energy-promoting effects of Palladium Lipoic Complex combined with a special combination of vitamins, minerals and amino acids crucial to the health and longevity of your pet. When Palladium is permanently bound to alpha lipoic acids, the bioavailability and rate of absorption into the body is greatly increased. Translated, this means that Poly-MVA for Pets is very beneficial to the health of your pet and is also fast-acting.

Extensive scientific studies and clinical use have proven that Poly-MVA for Pets is safe and non-toxic.

If your pet is facing a difficult illness, or treatment such as chemotherapy or radiation therapy, Poly-MVA may be just what you’re looking for. With minerals, vitamins and amino acids to keep your pet’s nutrition at its optimum, and Palladium Lipoic Complex to provide a healthy boost to cellular energy as well as for its powerful antioxidant characteristics, Poly-MVA for Pets is perfect for animals facing all types of health challenges.

Dosage suggestions for daily nutrition and well-being is 1/5 cc per 5 pounds of weight, twice a day. (Each 8 oz. bottle of Poly-MVA for Pets contains 236 liquid cc.) For pets with compromised immune systems, such as those undergoing chemotherapy or radiation treatments, dosage is to be increased gradually over 3-5 days to 1 cc per 5 pounds, twice a day. For very extreme or aggressive situations, we recommended the same gradual increase but doubling the dosage to 2 cc per 5 pounds, twice a day, until desired results are achieved.

Improving Quality of Life for Canine Cancer Patients

Monday, July 23rd, 2007
By Rick Shalvoy and Stephen Sinatra, M.D., F.A.C.C.

When large organizations plan to sponsor studies in human cancer, they have a number of distinguished cancer centers to approach for their clinical trials. In the field of veterinary oncology, Angel Care Cancer Center’s main hospital in Carlsbad, California offers diagnostic and therapeutic capabilities that are comparable to, and in many ways superior to, those at the finest human cancer centers in the world.

Angel Care Cancer Center has been studying Poly-MVA, a liquid dietary supplement, as an adjunct to cancer therapy since 2004. Invented by Dr. Merrill Garnett in 1991, Poly-MVA (MVA = a proprietary mixture of minerals, vitamins and amino acids) was introduced in 1995. While Dr. Garnett’s formulation is designed to increase cellular energy and enhance an animal’s quality of life during this difficult period of cancer treatment, it also takes advantage of cancer cell dysfunction to facilitate the animal’s recovery.

Among the nearly 800 patients involved in the Poly-MVA study over the past three years, the ones with the most delighted owners are those who enjoy a good quality of life with stable disease (cancer that does not progress). While virtually all these animals have been receiving DHA in addition to Poly-MVA, as well as specific therapies including surgery, chemotherapy and radiation where appropriate, there appears to be a subjective difference among some who had Poly-MVA added to their supplementation regimen compared to those who did not. Randomized, placebo controlled clinical trials have been proposed to confirm these observations.

“We see our best results among those patients that are treated long term with osteosarcoma, anal sac adenocarcinoma (cancer that originates in the anal sacs below the tail), hemangiosarcoma (a cancer of blood vessels) and many others,” says Angel Care’s director Dr. Gregory Ogilvie, who has been exploring the therapeutic potential of nutrients to treat veterinary cancer patients since 1984 and has published over 100 scientific articles on the subject. Dr. Ogilvie does not believe that every patient with every tumor will experience an observable benefit with Poly-MVA. (Lymphoma cases, for example, generally do not seem to improve.)

When asked if he would recommend Poly-MVA for veterinary cancer patients, Dr. Ogilvie says, “I would not be involved in Poly-MVA research if I did not believe it would help the majority of my patients experience an improved quality of life. “More formalized studies are needed before any definitive statements can be made regarding a statistically significant difference in survival.”

A client education booklet published by the center notes there is also much evidence to support supplementation with omega-3 (n-3 series) fatty acids, specifically docosahexaenoic acid (DHA), a long chain fatty acid that has been shown to have a number of benefits for the veterinary cancer patient. Most notably, DHA

• can inhibit tumor growth and development, and;
• appears to be important in reducing radiation and chemotherapy induced toxicity while increasing the efficacy of these therapies.

The booklet goes on to say that DHA from algae may be preferred, since fish sources can be contaminated with heavy metals and organophosphates (chemicals used in pesticides).

Algae-based DHA is available in gel caps at natural health pharmacies. Small dogs and cats should receive 200 mg once daily; medium sized dogs 200 mg twice daily; large breed dogs 200 mg three times daily; and giant breeds 200 mg four times daily.

Note: Quality of life (QOL) is the centerpiece gem of any study designed to evaluate the effectiveness of adjunctive modalities for cancer patients. It can be measured with a set of parameters (appetite, energy, behavior patterns, etc.) that are recorded and documented over time. For the Poly-MVA study, a significant number of people who have animals with cancer completed QOL surveys and returned them to Angel Care Cancer Center. Although many survey responses are based on clients' subjective impressions, an impressive 86% of respondents felt that Poly-MVA improved their animal's quality of life. The patients most likely to benefit included those that had a diminished quality of life prior to treatment.

Patients receiving Poly-MVA along with standard treatments for their cancers also tended to improve when it came to objective parameters such as weight, anemia, liver and kidney function, all of which have been monitored by the professional staff at Angel Care. Dr. Ogilvie, a scientific purist of the highest caliber, cautions that some patients will always respond much better than others in any study, but even he seems impressed by the overall trend that has been observed so far.

PolyMVA Research Articles

PolyMVA Information Packet - Garnett McKeen Laboratory Inc. (PDF, 105 kb)